Personalized EGFR tyrosine kinase inhibitor (EGFR-TKI) targeted therapy is currently the standard first-line treatment for patients with advanced EGFR-mutant NSCLC, but drug resistance is still inevitable [3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.